Score Overview
PeriodNet IncomeRevenueScoreGrowthTrendConsistencyGrowthTrendConsistency
5 Years
0.9
-326.31%
Never
—
-97.59%
40%
—
5 Years
Score0.9
Net Growth-326.31%
Net TrendNever
Net Income Consistency—
Rev Growth-97.59%
Rev Trend40%
Revenue Consistency—
Celldex Therapeutics Inc fundamental performance
Between 2015 and 2025, revenue declined from $ 5M to $ 1M and net income went from -$ 127M to -$ 258M. Revenue increased in 4 of those 10 years; net income in 2.
Across Celldex Therapeutics Inc's full reported history, from 2008 to 2025, revenue declined from $ 7M to $ 1M and net income went from -$ 47M to -$ 258M. Revenue increased in 50% of the years measured; net income in 22%.
Celldex Therapeutics Inc currently holds a 5-year HDB Score of 0.9 out of 10. How the HDB Score is calculated.
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-08-12 | $ 44.87 | — |
1 Year2025-08-12 | $ 23.80 | 88.53% |
5 Years2021-08-12 | $ 45.16 | -0.64% |
10 Years2016-08-12 | $ 66.90 | -32.93% |
20 Years2006-08-11 | $ 255.60 | -82.45% |
30 Years1996-08-12 | $ 472.50 | -90.50% |
All Time2008-03-10 | $ 114.45 | -60.80% |
| Period | Last Price2026-08-12 | 1 Year2025-08-12 | 5 Years2021-08-12 | 10 Years2016-08-12 | 20 Years2006-08-11 | 30 Years1996-08-12 | All Time2008-03-10 |
|---|---|---|---|---|---|---|---|
| Price | $ 44.87 | $ 23.80 | $ 45.16 | $ 66.90 | $ 255.60 | $ 472.50 | $ 114.45 |
| Return | — | 88.53% | -0.64% | -32.93% | -82.45% | -90.50% | -60.80% |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
| Year | |||
|---|---|---|---|
| 2026 | $ 112K | -$ 300M | $ 717M |
| 2025 | $ 1M | -$ 258M | $ 518M |
| 2024 | $ 7M | -$ 157M | $ 725M |
| 2023 | $ 6M | -$ 141M | $ 421M |
| 2022 | $ 2M | -$ 112M | $ 304M |
| 2021 | $ 4M | -$ 70M | $ 408M |
| 2020 | $ 7M | -$ 59M | $ 194M |
| 2019 | $ 3M | -$ 50M | $ 64M |
| 2018 | $ 9M | -$ 151M | $ 94M |
| 2017 | $ 12M | -$ 93M | $ 139M |
| 2016 | $ 6M | -$ 128M | $ 189M |
| 2015 | $ 5M | -$ 127M | $ 289M |
| 2014 | $ 3M | -$ 118M | $ 201M |
| 2013 | $ 4M | -$ 81M | $ 302M |
| 2012 | $ 11M | -$ 59M | $ 83M |
| 2011 | $ 9M | -$ 44M | $ 53M |
| 2010 | $ 46M | -$ 2M | $ 61M |
| 2009 | $ 15M | -$ 36M | $ 82M |
| IPO2008 | $ 7M | -$ 47M | $ 44M |
Explore beyond CLDX
You're looking at Celldex Therapeutics Inc. Members apply the same fundamental framework across all 3,860 companies we cover.
- Every HDB Score — 1, 5, 10, 20 and 30 years, plus all-time
- Revenue and Net Income Consistency for every period
- Rank all 3,860 companies by any metric, not just three
- Filter by sector and currency, and page through the whole list
- Track your holdings in a portfolio
$99/year $149 founding price
Unlock Holder Dashboard30-day money-back guarantee.
